Vertex Pharmaceuticals edges out Dyne Therapeutics as the better biotech buy for 2026

The Motley Fool··Read original
2▲1 ▼1Impact / 5
Summary · why it matters

Vertex Pharmaceuticals is favored over Dyne Therapeutics as the better drug innovator stock for 2026, according to an analysis by The Motley Fool. Dyne Therapeutics is a clinical-stage company with no revenue, reporting a net loss of $446.2 million in fiscal 2025, while Vertex posted $12 billion in revenue and nearly $4 billion in net income. Vertex's cystic fibrosis portfolio now covers 95% of U.S. patients and is expanding globally, with a promising pipeline including povetacicept for IgA nephropathy. Dyne's first product for Duchenne muscular dystrophy is expected in early fiscal 2027, with analysts projecting $53 million in sales that year and over $1 billion by 2030. Despite Dyne's growth potential, Vertex's strong profitability, heavy R&D investment, and reasonable forward price-to-earnings ratio make it the preferred choice.

Impact on assets 3

Biotech & Genomic Medicine± Mixed · 3 stocks
Dyne Therapeutics Inc
DYN
▼ NegativeCapitalrelevance

Dyne Therapeutics is a clinical-stage company with no revenue and a net loss of $446.2 million, making it less attractive compared to Vertex

Vertex Pharmaceuticals Inc
VRTX
▲ PositiveCapitalrelevance

Vertex has strong profitability ($12B revenue, $4B net income), a promising pipeline, and a reasonable forward P/E ratio, making it the preferred biotech buy

© 2026 MarketIVNews